Frova (frovatriptan succinate) first for female migraine sufferers

In a double-blind, placebo-controlled study1

FROVA® demonstrated efficacy

Of the early-dose patients a proportion of responders were completely migraine free1,a

  • 28% at 2 hours (vs 20% placebo, P=0.04)
  • 58% at 4 hours (vs 44% placebo, P=0.003)

aCompletely migraine free was defined as IHS grade 0 (absence of headache)1,2

Lisa, 41, has moderate-to-severe migraines, especially around her time of menstruation (Rollover to view Lisa's patient profile
Proportion of patients with mild or no headache at 2 hours and 4 hours postdose. Frova early dose. Frova later dose (placebo).
At 2 and 4 hours
Recurrence
Study design/Reference
Important Safety Information additonal Vermont prescriber information is available
FR-0270-01/June 2008